At the EAHAD Congress in 2024, Hemab Therapeutics Unveils Encouraging Initial Findings for Their Drug, HMB-001, Targeting Glanzmann's Thrombasthenia.

Chugai Pharmaceutical announced that China's National Medical Products Administration approved its innovative C5 monoclonal antibody, crovalimab.

In a Phase 2b clinical trial, the experimental oral peptide known as JNJ-2113 has shown encouraging outcomes for patients with moderate to severe psoriasis.

REGENXBIO Confirms Major Milestone Reached in Crucial Study of RGX-121 as Therapy for MPS II, Successfully Hitting Primary Goal.

Zymedi has begun first human trials of ZMA001, a novel monoclonal antibody for treating Pulmonary Arterial Hypertension.

Encoded Therapeutics Reveals Approval from US FDA for IND Application and Consent from Australian Health Authorities for ETX101, a Genetic Treatment Prospect for Dravet Syndrome.

Scholar Rock's Study Reveals SRK-439's Potential Influence on Muscle Mass and Metabolic Health in Weight Loss Efforts.

Orchard Therapeutics Reveals Enrollment of Initial Participant in Key Study of OTL-203 Targeting Hurler's Syndrome in MPS-I.

Rani Therapeutics Reports Encouraging Initial Outcomes from Phase 1 Trial of Oral RT-111, an Anti-IL-12/23 Antibody.

Johnson & Johnson has announced encouraging initial findings from a critical Phase 3 trial with nipocalimab for treating generalized myasthenia gravis, as well as from a Phase 2 investigation in Sjögren's Disease.

The Stage 2 trial for Technoderma's drug, TDM-105795, reveals positive outcomes for hair regeneration in individuals with pattern baldness.

Sangamo Therapeutics Reveals New Findings from Phase 1/2 STAAR Research for Fabry Disease Indicating Continuous Efficacy and Unique Safety Data.